MX2021003164A - Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas. - Google Patents

Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.

Info

Publication number
MX2021003164A
MX2021003164A MX2021003164A MX2021003164A MX2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A
Authority
MX
Mexico
Prior art keywords
methods
pancreatic cancer
patient
evaluation
cell
Prior art date
Application number
MX2021003164A
Other languages
English (en)
Inventor
Francois Collin
Chin - Jen Ku
Patrick A Arensdorf
Samuel Levy
Original Assignee
Bluestar Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluestar Genomics Inc filed Critical Bluestar Genomics Inc
Publication of MX2021003164A publication Critical patent/MX2021003164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/164—Methylation detection other then bisulfite or methylation sensitive restriction endonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Databases & Information Systems (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Physics (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Pure & Applied Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Operations Research (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Probability & Statistics with Applications (AREA)
  • Primary Health Care (AREA)
  • Algebra (AREA)

Abstract

En este documento se describen métodos para identificar pacientes con cáncer de páncreas y sujetos en riesgo de desarrollar cáncer de páncreas, métodos para monitorear a un paciente con una lesión pancreática identificada, métodos para evaluar la efectividad de un tratamiento usado para un paciente con cáncer de páncreas y métodos para seleccionar una terapia para tratar el cáncer de páncreas en un paciente en particular. La invención hace uso de biomarcadores de hidroximetilación, que en combinación con uno o más parámetros clínicos y opcionalmente uno o más tipos adicionales de biomarcadores y/o factores de riesgo específicos del paciente, exhiben un nivel de hidroximetilación que se correlaciona con el cáncer de páncreas. También se proporcionan kits y otros métodos de uso.
MX2021003164A 2018-09-19 2019-09-19 Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas. MX2021003164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733566P 2018-09-19 2018-09-19
PCT/US2019/052026 WO2020061380A1 (en) 2018-09-19 2019-09-19 Cell-free dna hydroxymethylation profiles in the evaluation of pancreatic lesions

Publications (1)

Publication Number Publication Date
MX2021003164A true MX2021003164A (es) 2021-06-23

Family

ID=68343435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003164A MX2021003164A (es) 2018-09-19 2019-09-19 Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.

Country Status (9)

Country Link
US (2) US20200123616A1 (es)
EP (1) EP3853383A1 (es)
JP (1) JP2022501033A (es)
CN (1) CN113508181A (es)
AU (1) AU2019343931A1 (es)
CA (1) CA3112880A1 (es)
MX (1) MX2021003164A (es)
SG (1) SG11202102421PA (es)
WO (1) WO2020061380A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115851942A (zh) * 2020-12-22 2023-03-28 上海市第一人民医院 诊断标志物gata4在胰腺“炎癌转化”中的应用
WO2022271857A1 (en) * 2021-06-23 2022-12-29 Accuragen Holdings Limited Gene expression and cell-free dna methods and systems for disease detection
KR20240063034A (ko) * 2022-10-31 2024-05-09 주식회사 지씨지놈 간암 진단용 dna 메틸화 마커 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712126A (en) 1995-08-01 1998-01-27 Yale University Analysis of gene expression by display of 3-end restriction fragments of CDNA
US6287825B1 (en) 1998-09-18 2001-09-11 Molecular Staging Inc. Methods for reducing the complexity of DNA sequences
CA2526284C (en) 2003-06-25 2014-11-18 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
US7537897B2 (en) 2006-01-23 2009-05-26 Population Genetics Technologies, Ltd. Molecular counting
CN101720359A (zh) 2007-06-01 2010-06-02 454生命科学公司 从多重混合物中识别个别样本的系统和方法
US20090093378A1 (en) 2007-08-29 2009-04-09 Helen Bignell Method for sequencing a polynucleotide template
US9115386B2 (en) 2008-09-26 2015-08-25 Children's Medical Center Corporation Selective oxidation of 5-methylcytosine by TET-family proteins
US20100323348A1 (en) 2009-01-31 2010-12-23 The Regents Of The University Of Colorado, A Body Corporate Methods and Compositions for Using Error-Detecting and/or Error-Correcting Barcodes in Nucleic Acid Amplification Process
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
WO2011127136A1 (en) * 2010-04-06 2011-10-13 University Of Chicago Composition and methods related to modification of 5-hydroxymethylcytosine (5-hmc)
AU2011289284B2 (en) * 2010-08-13 2015-04-09 Somalogic Operating Co., Inc. Pancreatic cancer biomarkers and uses thereof
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
EP2723896B1 (en) * 2011-06-23 2017-03-01 The Johns Hopkins University Mutations in pancreatic neoplasms
PT3363901T (pt) 2012-02-17 2021-01-22 Hutchinson Fred Cancer Res Composições e métodos para identificar mutações com precisão
EP4234713A3 (en) 2012-03-20 2024-02-14 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
WO2017176630A1 (en) * 2016-04-07 2017-10-12 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna
US20170298422A1 (en) 2016-04-18 2017-10-19 The Board Of Trustees Of The Leland Stanford Junior University Simultaneous single-molecule epigenetic imaging of dna methylation and hydroxymethylation
CN107385050A (zh) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 用于检测胰腺癌的基因标志物、试剂盒及胰腺癌检测方法
CN112105626A (zh) 2018-02-14 2020-12-18 蓝星基因组股份有限公司 用于dna、特别是细胞游离dna的表观遗传学分析的方法

Also Published As

Publication number Publication date
EP3853383A1 (en) 2021-07-28
SG11202102421PA (en) 2021-04-29
AU2019343931A1 (en) 2021-05-13
JP2022501033A (ja) 2022-01-06
WO2020061380A1 (en) 2020-03-26
US20200123616A1 (en) 2020-04-23
CN113508181A (zh) 2021-10-15
CA3112880A1 (en) 2020-03-26
WO2020061380A9 (en) 2020-05-28
US20240026459A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MX2021003164A (es) Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.
CO2020012588A2 (es) Composiciones de inhibidores de shp2, métodos para tratar el cáncer y metodos para identificar a un sujeto con mutaciones de shp2
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
CY1122871T1 (el) Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1
MX2021008797A (es) Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2005010486A3 (en) Biomarker panel for colorectal cancer
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
WO2004001072A3 (en) Method for diagnosis of colorectal tumors
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
AR080361A1 (es) Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2017214373A8 (en) Diagnostic and therapeutic methods for cancer
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
MX2017003406A (es) Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
Moratin et al. The occurrence of cervical metastases in squamous cell carcinoma of the tongue: is there a rationale for bilateral neck dissection in early-stage tumors?
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
AR085837A1 (es) Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer
WO2017165766A3 (en) Biomarkers of proteopathies and uses thereof
Cariati et al. Intraoperative cytological examination of bone medullary. A useful technique to predict the extension of bone invasion in segmental mandibulectomy
EA202090439A1 (ru) Способы и материалы для оценки и лечения рака